Laboratories

ACCREDITED LABORATORIES

Laboratories that wish to perform the analysis of doping controls for sports under the World Anti-Doping Code must achieve and maintain accreditation from WADA.  The International Standard for Laboratories (ISL) and its related technical documents specify the criteria that must be met for accreditation and re-accreditation, as well as standards that must be met for the production of valid test results and evidentiary data.

APPROVED LABORATORIES

To fully serve the development of the Athlete Biological Passport (ABP), particularly in regions where the current network of WADA-accredited laboratories may be limited, WADA has approved these laboratories to conduct blood analyses in support of the ABP.

Technical Documents

WADA publishes, from time to time, specific technical requirements, addressing particular operational areas of the accredited laboratories, in a Technical Document.

The Technical Documents constitute level-2 elements of the World Anti-Doping Program, and therefore implementation of the technical recommendations described in them is mandatory and must occur by the effective date specified in the Technical Document.

Technical Documents supersede any previous publication on a similar topic, or if applicable, the International Standard for Laboratories (ISL). The document in effect is the Technical Document whose effective date most recently precedes that of sample receipt date by the laboratory.

Technical Documents In Effect

Technical Document
In force
(in alphabetical order)

Summary of modifications

Effective Date*

TD2021BAR

TD2021BAR - Summary of modifications

1 Jun. 2021

TD2021LCOC

TD2021LCOC- Summary of modifications

1 Apr. 2021

TD2021DBS

N/A

1 Sep. 2021

TD2021EAAS

TD2021EAAS- Summary of modifications

1 Jun. 2021

TD2021EPO TD2021EPO - Summary of modifications

1 Sep. 2021

TD2021IDCR

TD2021IDCR- Summary of modifications

1 Apr. 2021

TD2021APMU

TD2021APMU - Summary of modifications

1 Apr. 2021

TD2021CG/LH

TD2021CG/LH- Summary of modifications

1 Apr. 2021

TD2021DL

TD2021DL - Summary of modifications

1 Apr.  2021

TD2021IRMS

TD2021IRMS - Summary of modifications

1 Jun.  2021

TD2021GH

TD2021GH- Summary of modifications

1 Apr. 2021

TD2021LDOC

TD2021LDOC- Summary of modifications

1 Apr. 2021

TD2019MRPL

TD2019MRPL - Summary of modifications

15 May 2019

TD2021NA

TD2021NA - Summary of modifications

1 Jun. 2021

* Deadline for implementation

RECENTLY APPROVED** VERSIONS OF TECHNICAL DOCUMENTS:

Technical Document
(in alphabetical order)

Summary of modifications

Approval Date

Effective Date**

** As per the International Standard for Laboratories, Technical Documents are posted on WADA’s website when approved by the WADA Executive Committee and may be applied prior to the effective date for implementation. The newly approved Technical Document replaces the previous effective version and becomes the mandatory version for all stakeholders by its effective date, which represents the deadline for its mandatory implementation.

TECHNICAL LETTERS

WADA publishes Technical letters on an ad-hoc basis in order to provide instruction and guidance to the Laboratories, WADA-Approved Laboratories for the ABP and other stakeholders on particular issues related to the analysis, interpretation and reporting of results for specific Prohibited Substance(s) and/or Prohibited Method(s) or on the application of specific Laboratory procedures. Technical Letters are modified and/or withdrawn by WADA as deemed appropriate.

The Technical Letters constitute a WADA Laboratory standard document which supersedes any previous publication on a similar topic and becomes an integral part of the International Standard for Laboratories (ISL), and therefore the described technical recommendations are mandatory and shall be implemented as soon as possible after approval by the WADA Executive Committee and publishing on WADA’s website.

A Technical Letter shall be applied to samples which are received by the Laboratory on and after the Technical Letter’s effective date.

TECHNICAL LETTERS IN EFFECT

Title

Document Number

Version Number

Effective Date

Summary of Modifications for 2021 Technical Letters

Meclofenoxate

TL01

3.0

01 Jan 2021

Mebeverine Metabolism

TL02

3.0

01 Apr 2021

Zeranol

TL04

3.0 01 Jan 2021

Oxilofrine

TL05

3.0 01 Jan 2021

Possible Metabolism of Proguanil into Chlorazanil

TL06

3.0 01 Jan 2021

Andarine - Flutamide

TL07

3.0 01 Jan 2021

Use of Internal Standards

TL08

3.0

01 Jan 2021

Oxethazaine

TL09

3.0 01 Jan 2021

In situ Formation of Exogenous Compounds

TL10

3.0 01 Jan 2021

Oxymorphone

TL11

3.0

01 Apr 2021

Ostarine

TL12

3.0 01 Jan 2021

Trimetazidine

TL13

3.0 01 Jan 2021

Difference in “A” and “B” Sample Urine Characteristics

TL14

3.0 01 Jan 2021

Hydromorphone

TL15

3.0 01 Jan 2021

Tretoquinol

TL16

3.0 01 Jan 2021

Detection of Tulobuterol in the presence of Bupropion

TL17

3.0 01 Jan 2021

Testolactone

TL18

2.0

01 Jan 2021

Prednisone and Prednisolone

TL19

3.0 01 Jan 2021

Specific substances with a steroid structure

TL20

2.0

01 Jan 2021

In Situ Formation of 4-androstene-3,6,17-trione (6-oxo) and Metabolites

TL21

2.0

01 Jan 2021
Ethylmorphine TL22 3.0 01 May 2021
Growth Promoters TL23 1.0 01 June 2021
Diuretics TL24 1.0 01 June 2021

RECENTLY APPROVED* VERSIONS OF TECHNICAL letters:

Document number

Version number

Approval Date

Effective Date**

Summary of Modifications for 2021 Technical Letters

* As per the International Standard for Laboratories (ISL), Technical Letters are posted on WADA’s website following approval by the WADA Executive Committee. The newly approved Technical Letter replaces the previous effective version and becomes the mandatory version for all Signatories by its effective date, which represents the deadline for its mandatory implementation.

GUIDELINES

WADA publishes guidelines relating to doping control activities.

In cooperation with WADA, the International Anti-Doping Agreement (IADA) has also developed guidelines for Anti-Doping Organizations that have already obtained an ISO certification or that wish to be ISO-certified. These are: Guidelines for Transition and Guidelines for Certification.

As with all guidelines under the World Anti-Doping Program, these documents are subject to ongoing review and reassessment.

WADA encourages feedback on the content of the Guidelines, and recommends that stakeholders always consult this Web site for the latest version.

Laboratory Guidelines currently in force:

Laboratory Guideline

Version number

Summary of Modifications for 2021 Laboratory Guidelines
Human Growth Hormone (hGH) Biomarkers Test

3.0

TUE enquiries by Accredited Laboratories

4.0

Conducting and Reporting Subcontracted Analysis and Further Analysis for Doping Control

3.0

Gene Doping Detection based on Polymerase Chain Reaction (PCR)
 
1.0

LABORATORY TESTING FIGURES

In accordance with Article 14.5 of the World Anti-Doping Code (the Code), WADA, acting as a central clearinghouse for Doping Control data, annually publishes statistical reports as reported by the WADA accredited laboratories in the Anti-Doping Administration and Management System (ADAMS).

The latest WADA Anti-Doping Testing Figures Report can be accessed here

For a more complete overview of the Testing Figures, please consult the comprehensive Questions and Answers document.

LABORATORY ASSESSORS

Collaboration between WADA and the International Laboratory Accreditation Cooperation (ILAC) provides an important opportunity to conduct the International Standard for Laboratories (ISL) assessment concurrently with the ISO/IEC 17025 assessment for the WADA accredited anti-doping laboratories.

The List of ISL Assessors contains the names of the assessors from ILAC-member accreditation bodies trained by WADA for
the ISL assessment.